Scots-Knight Denise 4

What Happened

• Denise Scots‑Knight, a non‑employee director of Elanco Animal Health Inc. (ELAN), was granted two equity awards on May 21, 2026: 4,678 deferred stock units (DSUs) and 12,196 restricted stock units (RSUs). Both grants are reported at $0.00 per share (awarded for compensation), totaling 16,874 units acquired by award.
• These awards are director compensation rather than open‑market purchases or sales, so they are routine remuneration and do not on their own signal a personal cash investment.

Key Details

• Transaction date: 2026-05-21. Filing date (Form 4): 2026-05-26.
• Transaction code: A = Award/Grant. Price reported: $0.00 for both grants.
• Shares/units granted: 4,678 DSUs (F1) and 12,196 RSUs (F2) — total 16,874 units.
• Footnotes from the filing:
  • F1: DSUs granted as a pro‑rated annual equity award to non‑employee board members.
  • F2: RSUs granted as the annual equity award to non‑employee board members.
• Shares owned after the transaction: not specified in the provided filing details.
• Timeliness: Filed 2026-05-26 — appears timely (the two‑business‑day filing window was affected by the May 25 federal holiday).

Context

• DSUs and RSUs are common forms of director compensation. DSUs are typically deferred and may convert to shares (or cash) under company plan terms; RSUs generally vest into shares subject to the issuer’s vesting/settlement rules. Check the company’s proxy or equity plan for specific vesting/settlement terms.
• Because these were awards (not purchases or sales), they reflect compensation policy rather than a director buying or selling stock in the open market.